Tulisokibart

图索奇拜单抗

Report date: 2026/05/28 20:00:21

Base Information

Drug NameTulisokibart
Drug Alias NamePRA-023MK-7240PRA023
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor superfamily member 15 inhibitors
TargetsTumor necrosis factor superfamily member 15
Therapy Area/IndicationsNon-radiographic axial spondyloarthritisAxial SpondyloarthritisScleroderma, Diffuse +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPrometheus Biosciences IncMerck Sharp & Dohme LLC
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLCPrometheus Biosciences IncMSD R&D（China）Co Ltd
Inactive CompaniesN/A
Active IndicationsNon-radiographic axial spondyloarthritisAxial SpondyloarthritisScleroderma, Diffuse +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A